Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Facts Label Should Be Required On Immediate Package – ONP’s Ganley

This article was originally published in The Tan Sheet

Executive Summary

Allowing the sale of OTC drugs in packages without Drug Facts labels on the immediate container poses risks for consumers, FDA Office of Nonprescription Products Director Charles Ganley says

You may also be interested in...



FDA Will Cooperate With OTC Drug Industry To Address Labeling Questions

FDA will work cooperatively with industry to address complications that may arise from the final rule on standardized OTC labeling announced March 11, Commissioner Jane Henney, MD, told the Nonprescription Drug Manufacturers Association annual meeting in Boca Raton, Fla. March 12 (see related stories, pp. 4-10). NDMA is being renamed the Consumer Healthcare Products Association.

Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag

Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.

OTC Incontinence Device Ad Claims Sunk In UK, But US Label Claims Have FDA OK

UK ASA upholds complaints that questioned claims made in 2018 TV ads that Innovo was clinically proven to strengthen the pelvic floor and treat bladder weakness. In the US, however, claims Atlantic Therapeutics will use to promote OTC sales of Innovo were approved by FDA.

Topics

UsernamePublicRestriction

Register

PS100003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel